NDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Baycol is a statin (HMG-CoA reductase inhibitor) approved in 1997 for lowering cholesterol and reducing cardiovascular risk in patients with hyperlipidemia. It is administered orally as a tablet and works by inhibiting cholesterol synthesis in the liver. The product is currently approaching loss of exclusivity.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely consolidating rather than expanding, signaling potential downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Baycol offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Professionals on this brand should expect consolidation, optimization focus, and potential reassignment to pipeline products or higher-growth franchises.
Brand ManagerCommercial Operations
Worked on BAYCOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.